Dr. Haydar A. Frangoul
Claim this profileThe Children's Hospital at TriStar Centennial
Area of expertise
Cancer
Haydar A. Frangoul has run 12 trials for Cancer. Some of their research focus areas include:
Neuroblastoma
Haydar A. Frangoul has run 9 trials for Neuroblastoma. Some of their research focus areas include:
Affiliated Hospitals
The Children's Hospital At TriStar Centennial
TriStar Medical Group Children's Specialists
Clinical Trials Haydar A. Frangoul is currently running
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting
2 awards
Phase 3
Chemotherapy
for Cancer
This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Chemotherapy drugs, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating metastatic standard risk germ cell tumors.
Recruiting
2 awards
Phase 3
26 criteria
More about Haydar A. Frangoul
Clinical Trial Related
8 years of experience running clinical trials · Led 33 trials as a Principal Investigator · 7 Active Clinical Trials
Treatments Haydar A. Frangoul has experience with
- Cyclophosphamide
- Etoposide
- Radiation Therapy
- Vincristine Sulfate
- Carboplatin
- Cisplatin
Breakdown of trials Haydar A. Frangoul has run
Cancer
Neuroblastoma
Brain Tumor
Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Haydar A. Frangoul specialize in?
Haydar A. Frangoul focuses on Cancer and Neuroblastoma. In particular, much of their work with Cancer has involved Stage I patients, or patients who are Stage IV.
Is Haydar A. Frangoul currently recruiting for clinical trials?
Yes, Haydar A. Frangoul is currently recruiting for 7 clinical trials in Nashville Tennessee. If you're interested in participating, you should apply.
Are there any treatments that Haydar A. Frangoul has studied deeply?
Yes, Haydar A. Frangoul has studied treatments such as Cyclophosphamide, Etoposide, Radiation Therapy.
What is the best way to schedule an appointment with Haydar A. Frangoul?
Apply for one of the trials that Haydar A. Frangoul is conducting.
What is the office address of Haydar A. Frangoul?
The office of Haydar A. Frangoul is located at: The Children's Hospital at TriStar Centennial, Nashville, Tennessee 37203 United States. This is the address for their practice at the The Children's Hospital at TriStar Centennial.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.